Quantifying Her2 Protein for Optimal Cancer Therapy

摘要

Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.

主权项

1. A method of treating a patient suffering from cancer comprising:
(a) quantifying the level of a specified Her2 fragment peptide in a protein digest prepared from a tumor sample obtained from the patient and calculating the level of the Her2 peptide in said sample by selected reaction monitoring using mass spectrometry; (b) comparing the level of said Her2 fragment peptide to a reference level, and (c) treating the patient with a therapeutic regimen comprising an effective amount of an anti-Her2 therapeutic agent when the level of the Her2 fragment peptide is higher than said reference level or (d) treating the patient with a therapeutic regimen that does not comprise an effective amount of an anti-Her2 therapeutic agent when the level of the Her2 fragment peptide is below said reference level.